Novo Nordisk's Once-Weekly Insulin Flagged With Risk Of Low Blood Sugar Ahead Of FDA Review
Portfolio Pulse from Vandana Singh
Novo Nordisk's once-weekly insulin icodec faces scrutiny from the FDA due to increased risk of low blood sugar in type 1 diabetes patients. The FDA's review has been extended by three months, with a decision expected in Q3 2024. Novo Nordisk has proposed labeling to mitigate risks.
May 22, 2024 | 5:21 pm
News sentiment analysis
Sort by:
Ascending
NEGATIVE IMPACT
Novo Nordisk's once-weekly insulin icodec is under FDA review due to increased risk of low blood sugar in type 1 diabetes patients. The review has been extended by three months, with a decision expected in Q3 2024. This could impact the stock negatively in the short term.
The FDA's concerns about the increased risk of low blood sugar and the extension of the review period introduce uncertainty around the approval of insulin icodec. This could negatively impact investor sentiment and the stock price in the short term.
CONFIDENCE 85
IMPORTANCE 90
RELEVANCE 100